Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits

May 16, 2017 By Law Offices of Thomas J. Lamb, P.A.

On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, “IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER — MDL No. 2776”, from which we get the following information:

On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization of these cases will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. The actions share factual questions arising from allegations that taking Farxiga or Xigduo XR may result in patients suffering kidney-related injuries, such as diabetic ketoacidosis and kidney damage. The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs.

The JPML went on to assign this new Farxiga MDL to Judge Lorna G. Schofield, who will preside over this consolidated litigation in the Southern District of New York federal court.

The FDA is investigating a connection between Farxiga and Xigduo XR — as well as Invokana, Invokamet, Jardiance, Glyxambi, Synjardy, and Qtern — with several different serious side effects, including diabetic ketoacidosis (DKA) and kidney damage.

All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.

We will continue to monitor legal and drug safety developments regarding Farxiga, Xigduo XR, and the several other SLGT2 inhibitor diabetes drugs.

[Read this article in full at original source]

____________________________________________

Invokana / Farxiga / Jardiance

Free Case Evaluation

Strictly Confidential, No Obligation.

____________________________________________

Filed Under: Unsafe Drugs Tagged With: Diabetic Ketoacidosis (DKA), Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Kidney Damage, Qtern, Synjardy, Xigduo

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.